Edgewise Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. It is publicly traded on Nasdaq under the ticker EWTX. The company applies integrated muscle physiology and small-molecule drug development to serious cardiovascular and cardiometabolic diseases, with a stated focus on precision therapeutics intended to preserve and protect muscle function.
Two lead programs are in Phase 2 development. EDG-7500 is being developed for hypertrophic cardiomyopathy. EDG-15400 is being developed for heart failure with preserved ejection fraction (HFpEF); the company has dosed the first patient in the Phase 2 EQUINOX-HFpEF trial of that candidate.
The company's technical work spans integrated muscle physiology, small-molecule drug development, precision therapeutics, and cardiovascular and cardiometabolic disease research. Its earlier focus was on muscular dystrophies before it concentrated its strategy on cardiovascular and cardiometabolic medicines.
Edgewise Therapeutics describes its approach as patient-centred and science-driven, and reports collaboration with researchers, clinicians, patient-advocacy organisations, patients and families.
